Class summary at a glance.

Every drug in the Interleukin-13 Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $123.6Mcombined across class
Total Rx claims: 27K7K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tralokinumab-Ldrm

Brand: Adbry · 23K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2022-01-02

Brand-only (no generics) 107 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $90.6M

Class share

73%

of class CY24 spend

View profile →

Lebrikizumab-Lbkz

Brand: EBGLYSS · 4K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2024-09-13

Brand-only (no generics) 28 plans require PA

Low NADAC$1795.81

→

Avg plan cost$1795.81

Part D spend $33.0M 1× spread, current vs floor

Class share

27%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.